News Hub | News Direct

InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need

Benzinga

By Meg Flippin, Benzinga Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all. The leader in cannabinoids and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization hit key milestones in advancing its cannabinoids-based treatments for Alzheimer’s disease, age-related macular degeneration (AMD) and epidermolysis bullosa in 2023 with more inroads to come in 2024. Take Alzehimer’s for starters. The disease is a big and growing problem afflicting about 6.7 million people 65 and older in the U.S. By 2060 it’s projected that 14 million people in the U.S. will suffer from the degenerative neurological disease. Treatments exist to address the symptoms related to memory and cognitive function and in some instances slow the rate of cognitive decline, but none have been able to reverse disease effects. Making An Impact InMed hopes to change that with INM-901, a rare cannabinoid analog the company says has the potential to target several biological pathways associated with Alzheimer’s. Previous industry research has shown cannabinoids hold promise in not only slowing the progress of Alzheimer’s but potentially reversing its effects thanks to their neuroprotective and regenerative properties. InMed’s data from preclinical i n vivo studies released last year showed INM-901 improved cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. To further evaluate INM-901 in 2024, InMed has initiated longer-term, six-month preclinical studies in behavior models. At the same time, the company is gearing up to launch more advanced preclinical studies, encompassing drug distribution, metabolism, active pharmaceutical ingredients and drug product formulation/manufacturing. Cannabinoids Can Protect Eyes Another big disease InMed is going after is age-related macular degeneration or AMD, which is a common cause of vision loss and potential blindness in people over 50. Based on 2019 estimates, AMD afflicts 19.8 million people or 12.6% of Americans 40 and up. Globally it affects 35% of people 74 and older. As it stands, there is no cure for AMD although treatment can prevent or slow the progression of the disease. Left unchecked patients may lose central field vision in the affected eye within 24 months of disease onset. INM-089, InMed’s ocular program for AMD launched in November is showing promise in changing that. Preclinical studies showed the potential for the drug to preserve retinal function, proactively protect the retinal cells that are responsible for vision and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated, InMed said. Coming off those positive results, InMed is engaged in advanced preclinical studies and drug product formulation work, and it plans to launch Investigational New Drug studies in mid-2024. The goal is to file an Investigational New Drug application with regulatory authorities in the first half of 2025. “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs,” said InMed CEO Eric A. Adams. “Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.” Dermatology Program Additionally, last year, the company successfully completed a phase 2 clinical trial in the treatment of epidermolysis bullosa or EB, a rare genetic skin disease marked by fragile skin that can lead to extensive blistering and wounding. Data from a phase 2 clinical trial of INM-755 showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone, warranting further development. InMed thinks INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments and is currently seeking partnerships for continued development. Supplier To All In addition to developing its own treatments, InMed is a key supplier of rare cannabinoids as ingredients to the health and wellness market. The company’s BayMedica unit focuses on being a low-cost/high-quality manufacturer of certain non-psychoactive rare cannabinoids and an ingredients supplier to brands within the health and wellness industry. In 2023, the company said the unit experienced “significant” year-over-year revenue growth, and it is making moves to capitalize on revenue-generating opportunities in 2024. To that end, BayMedica is embracing a distributor model to expand coverage across the U.S. InMed is betting consumer brands will use more rare cannabinoid ingredients in 2024 – and InMed will be ready to provide them. “BayMedica continues to drive robust year-over-year revenue growth. The foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoid ingredients continues to gain momentum,” said Adams. Cannabinoids hold promise to treat and potentially cure several diseases. InMed seems to be at the forefront of these groundbreaking advances. If 2023 is any indication, investors may want to watch for more milestones out of InMed this year and beyond. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 26, 2024 08:40 AM Eastern Standard Time

The best generative AI solutions of 2024

AIport

January 25, 2024 — Ever since ChatGPT burst onto the scene in the fall of 2022, generative AI (GenAI) solutions have continued to disrupt industries with their surprising and never-before-seen features. Many of the generative AI solutions we hear about today are based on large language models (LLM), which allow them to successfully communicate with end users. Every such model has to be pre-trained on vast amounts of data and then fine-tuned using a variety of different methods. As we’re approaching the end of January, let’s look at the list of the most noteworthy of these models and explore the generative AI solutions they power. Compiled by the AIport newsletter team, this list is by no means exhaustive, but it is a review of what we believe are the LLM-based generative AI solutions and tools that are likely to make headlines this year. GPT (OpenAI and Microsoft) Expectedly, the first LLM on our list with some of the highest expectations this year is at the core of ChatGPT from OpenAI. GPT wasn’t the first LLM out there (there had been others like BERT ), but it was certainly the first one that resulted in a market-ready GenAI product. The original GPT model (Generative Pretrained Transformers) had 170 billion parameters, while the latest version, GPT-4, boasts over 1.75 trillion. The model’s applications are far and wide, being the basis not only for ChatGPT, but also Microsoft’s Bing Chat, which is now part of the Copilot infrastructure. While ChatGPT remains arguably the most impressive text-producing GenAI tool, Bing Chat (unlike ChatGPT) has internet access, making it ideal for web browsing. In addition, the same core GPT model is being utilized by other entities — from Panasonic Connect in Japan, OCBC Bank’s ChatGPT in Singapore, and KPMG’s KaiChat in Germany to the UK government’s upcoming GOV.UK chat. Notably, GPT is also a vital part of OpenAI’s DALL-E suite — a solution that generates images based on descriptions from text. PaLM and Gemini (Google) The next one on our list is Google’s PaLM (Pathways Language Model). The model, boasting 540 billion parameters, was first successfully tested in the spring of 2022. A year later, PaLM 2 was announced and subsequently integrated into Bard — Google’s GenAI chatbot — becoming available to test users around the world. Bard is considered among the finest solutions for productivity, having internet access like Bing Chat, but being less about navigating the web and more about answering burning questions. Bard was seriously bolstered at the end of last year with Google’s highly anticipated launch of the multimodal LLM, Gemini, which had been trained on images and audio/video files, not just text. The jury is still out on how far this update will take Bard, but the expectations are very high indeed. LLaMA (Meta, Microsoft, and Hugging Face) LLaMA (Large Language Model Meta AI) from Meta was released in February last year. However, the 65-billion-parameter model was leaked online as a downloadable torrent only a week later. While the model did not lead to any ChatGPT-like products at Meta, another AI company — Hugging Face — picked it up and released Hugging Chat. Offering internet access, this GenAI solution has been praised as “the first open source alternative to ChatGPT” with a snarky sense of humor. Not to be outdone, Meta partnered with Microsoft to produce LLaMA 2 in July of last year. Following that, the company announced a beta release of Meta AI at the end of September — a GenAI chatbot, currently available in the US, that can “provide real-time information and generate photorealistic images” from text prompts. This solution is expected to reach Meta users across the rest of the globe later in the year. Claude (Anthropic) Our next LLM is made by Anthropic, and it’s named Claude. Founded in 2021, the company along with its language model may be a less familiar name to most non-geeks. But this is likely to change in 2024. That’s the case not only because the latest version of the namesake GenAI chatbot released last year can now process long PDF files of up to 75,000 words, taking moments to summarize entire books. But also because this has already caught the attention of both Google and Amazon who are keen to invest $2 and $4 billion respectively. While Claude doesn’t offer internet access, its processing power, namely input character memory, outpowers every competitor by a wide margin, including ChatGPT. And the company is said to be working on yet more handy features as we speak. HyperCLOVA X (Naver) HyperCLOVA X is both the LLM and the namesake GenAI chatbot released by the South Korean search engine giant, Naver, last August. Boasting over 200 billion parameters, the LLM is being used mainly for AI-assisted web browsing, much like Bing Chat. While HyperCLOVA X doesn’t speak English, the chatbot’s proficiency in Korean is impressive, having learned 6,500 more Korean words than ChatGPT. In addition to answering user queries, HyperCLOVA X has been designed to offer AI assistance to businesses across numerous sectors — from finance to gaming. Naver is also presently working to make HyperCLOVA X multimodal, following in the footsteps of Google’s Gemini, so another big international headline is likely on the way. Pangu (Huawei) Last spring, Huawei, one of the global tech leaders, unveiled Pangu — an LLM with 1.085 trillion parameters in over 40 natural and programming languages. This LLM now powers the Chinese company’s GenAI assistant called Celia, which resides within Huawei’s HarmonyOS 4 operating system. Supposedly, Celia has already outperformed both Siri and Google Assistant as a phone-based virtual assistant in terms of prompt execution accuracy, such as finding specific photos and documents stored on a device. And as more Huawei smartphones are being churned out, Celia is expected to reach more global users this year with further refinements to the Pangu model. In addition, Pangu is available through Huawei Cloud for commercial use. According to a statement from the company’s leadership, the newest Pangu 3.0 utilizes hierarchical architecture, allowing it to be quickly fine-tuned for a wide range of downstream applications (including Huawei’s autonomous vehicle solutions ), which we’ll surely see more of in 2024. MiLM-6B (Xiaomi) Next up is another Chinese company, Xiaomi — one of the largest phone manufacturers in the world. The company made an entry into the LLM race last summer with its MiLM-6B, a lightweight model created for mobile devices. Boasting 6.4 billion parameters, MiLM-6B has reportedly outperformed rivals in its category and achieved notable scores from evaluation platforms like C-Eval and CMMLU. Xiaomi’s leadership has been vocal for some time about integrating LLMs into its smartphones. It appears that the company’s virtual assistant, Xiao AI, has now finally become a fully fledged GenAI chatbot, generating over 11 words per second. By this metric, despite operating locally on the phone, Xiao AI has matched the performance of some LLMs running on cloud computing services. It’ll be interesting to see whether Xiao AI gets assimilated into the company’s other products, as the rumors suggest, including the recently announced Xiaomi SU7, an autonomous-enabled electric sedan. YandexGPT (Yandex) The final entry on our list is an LLM named YandexGPT from the Russian search engine Yandex. The namesake GenAI solution with 100 billion parameters was beta-released in May last year. The more recent release of YandexGPT2 has demonstrated a 65% improvement in response quality, with a 1.5-fold increase in training data. Interestingly, this GenAI solution was tested and scored enough points to enter a Russian university. YandexGPT was also integrated into Yandex’s flagship virtual assistant named Alice, as well as the company’s smart speakers. Furthermore, the LLM has allowed the company’s e-shoppers to view summarized customer reviews in one place. With YandexGPT at the core, the company now also offers visual GenAI solutions, YandexART and Shedevrum, that can generate images from text, much like Open AI’s DALL-E. Currently, the LLM is also being merged with Yandex Search to offer the end user something similar to Bing Chat and HyperCLOVA X. It’s likely that we’ll see a new announcement pertaining to this development later in the year. New kids on the block Apart from the above entries on our list, several brand new LLMs along with their GenAI solutions are expected to arrive any day from other big players. Among them are Samsung from South Korea, Tencent from China, as well as Amazon and Apple. In fact, Apple already has an internal AI chatbot for employees, but its much-talked-about AppleGPT based on the company’s LLM, Ajax, is said to be around the corner. Amazon began to offer a service for building AI chatbots called Lex a while ago, but more notably, the company recently announced its upcoming GenAI solution tailored for commercial use. Japan doesn’t intend to be left behind either — at least three major LLM initiatives are currently being played out. Among them is a joint project between Fujitsu, RIKEN, Tokyo Tech, and Tohoku University who are developing a series of LLMs using one of the world’s most powerful supercomputers, Fugaku. In addition, both NTT and SoftBank are reportedly in the final stages of developing their “homegrown” LLMs. While much remains unclear and covered in mist (or is it gray goo 😉), one thing is certain — 2024 is going to be the most AI-intense year we have seen yet! If you enjoyed this listicle, visit AIport for more exclusive insights into the latest tech trends, with a focus on the global ML landscape. All trademarks mentioned are the property of their respective owners. Contact Details NettResults PR Nick Leighton +1 949-478-5880 nick.leighton@nettresultsllc.com Company Website https://aiport.substack.com/

January 25, 2024 09:53 AM Pacific Standard Time

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem

Ness Ziona, Israel, January 25 th 2024, Kadimastem (TASE: KDST), a well-known biotech company in the field of cellular therapy, which is in the clinical development stages of innovative products for the treatment of ALS and diabetes, announced today the publication of the peer-reviewed prestigious journal of Clinical Toxicology. The article describes the development and safety of the new off the shelf cryopreserved AstroRx cell product in toxicity studies. Intrathecal injection of both low dose of DMSO (vehicle control) used for cryopreservation of human astrocytes and the cryopreserved AstroRx® cell product demonstrated high safety profile in mice. Link to the article. The article details the important milestone achieved by the company in the development of cryopreserved AstroRx® off the shelf cell product that will be thawed and injected near the patient's bedside. The development of a cryopreserved cell therapy product would allow the completion of more accurate and longer sterility testing, the completion of potency results, simplify the process of manufacturing scaling, enable long term storage and transport and facilitate timing of therapy delivery to the patient. The Cryopreserved product will help secure the clinical objectives of the upcoming IND approved phase IIa clinical trial in 30 ALS patients. Kadimastem's AstroRx® cell product is an allogeneic cell-based product composed of healthy and functional human astrocytes derived from embryonic stem cells. AstroRx® acts through multiple mechanisms of action that increase the survival of neurons, such as removal of toxic excessive glutamate, reduce oxidative stress, secrete various neuroprotective factors, and act as an immunomodulator. Dr. Michal Izrael, Kadimastem's VP R&D says: “The new formulation of cryopreserved of the shelf AstroRx® cell product (“thaw and inject”) is of great importance for product commercialization as well as to the success of our upcoming phase II clinical study, as it permits coordination of cell administration with patient care and completion of safety and quality control testing before cell administration.” Asaf Shiloni, Kadimastem’s CEO says: “We would like to thank Kadimastem's dedicated team for achieving this significant milestone. We are very excited to move towards our next Phase IIa clinical study approved by the FDA, with the new off-the-shelf AstroRx® cell product which will be tested using repeated intrathecal injections of AstroRx® in ALS patients.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Asaf Shiloni CEO s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

January 25, 2024 08:24 AM Eastern Standard Time

Image

Dr. Aaron Stowell's Comprehensive Hormone Therapy Program Emerges as a Game-Changer in the Pursuit of Weight Loss in Scottsdale

Rev Up Marketers

Dr. Aaron Stowell, NMD, proudly announces the groundbreaking success of his Comprehensive Hormone Therapy Program in redefining the approach to Weight Loss Hormone Therapy in Scottsdale. With an unwavering commitment to holistic health and innovative solutions, Dr. Stowell's program has become a transformative force in the realm of medical weight loss therapies. Overview of the Program Dr. Aaron Stowell's Hormone Therapy Program is revolutionizing the landscape of weight loss solutions in Scottsdale, Arizona. This program encompasses a holistic approach that acknowledges the individuality of each patient's body composition. By tailoring hormone therapy to meet personalized weight loss needs, Dr. Stowell's program stands out as a beacon of personalized medicine, placing Scottsdale Restorative at the forefront of this transformative movement. The Significance of Hormone Therapy in Weight Loss Hormone therapy offered at Scottsdale Restorative is not merely focused on weight reduction. Instead, it targets a comprehensive transformation by optimizing body composition, promoting the development of lean muscle mass, and reducing body fat percentage. This approach not only facilitates weight loss but also aids in sustaining healthier body changes and elevating overall fitness levels. Addressing Scottsdale's Weight Loss Needs The program recognizes the diverse nature of individual bodies and their unique weight loss challenges. Dr. Stowell's team is dedicated to providing a tailored approach, specifically addressing the weight loss needs of Scottsdale's residents. Through personalized hormone therapy, patients are empowered to achieve their health and wellness goals in a manner that acknowledges their distinct physiological makeup. Understanding the Role of Peptides in Weight Management Peptide hormones, naturally occurring compounds within the human body, are pivotal in regulating various physiological processes, including metabolism and appetite. Harnessing this intrinsic mechanism, the program has led to the development of advanced peptide-based formulations designed to support safe, effective, and sustainable weight loss. Implications for Future Healthcare Strategies Scottsdale Restorative is pioneering personalized, holistic care models to set a new standard. Its patient-centric approach and integration of technology redefine future healthcare strategies, emphasizing individualized, proactive wellness over standardized treatments. This visionary shift signals a transformative era in healthcare delivery. Collaborative Efforts and Future Prospects The collaborative patient-provider approach of Scottsdale Restorative drives innovative healthcare. Its vision embraces technological integration, promising future prospects in personalized medicine. This collaborative synergy foretells a healthcare landscape prioritizing patient involvement and pioneering advancements for comprehensive well-being. Dr. Aaron Stowell's Expertise and Vision With over 16 years of combined experience, Dr. Aaron Stowell, NMD, has spearheaded an evidence-based approach to managing health. His pioneering vision has positioned Scottsdale Restorative as the leader in bio-identical hormones, integrative medicine, and medical weight loss therapies. Dr. Stowell's unwavering commitment to compassionate care aimed at treating the root causes of health issues ensures lifelong wellness for patients. Summary Dr. Aaron Stowell's visionary leadership is a beacon of hope for individuals seeking effective and personalized solutions for Scottsdale weight loss. The comprehensive hormone therapy program represents a paradigm shift in the pursuit of holistic health, promising not only weight loss but sustainable changes that promote lifelong wellness. Disclaimer: The information presented in this press release is intended for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment. While Dr. Aaron Stowell, NMD, promotes a Comprehensive Hormone Therapy Program for weight loss, its effectiveness varies individually. Prior to initiating any hormone therapy or weight loss program, it is essential to consult with a qualified healthcare professional. This content does not replace medical advice, and individuals considering participation in the program should seek guidance from their healthcare provider based on their specific health conditions and medical history. The use of peptides and treatments discussed should be supervised by a qualified healthcare professional. Contact Details Dr. Aaron Stowell Dr. Aaron Stowell NMD contact@scottsdalerestorative.com Company Website https://drstowell.com/

January 24, 2024 01:28 PM Eastern Standard Time

Image

Centre for Neuro Skills Announces New General Counsel

Centre for Neuro Skills

Bakersfield, Calif. (Jan. 24, 2024) Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, today announced the appointment of Jamie Mason, J.D., as general counsel. “Jamie has extensive in-house counsel experience and a strong background in healthcare,” says Nicholas Ashley, chief governance officer of Centre for Neuro Skills. “She is a fast learner and quickly integrated herself with the team. We are fortunate to have her in the company to keep us moving forward.” Mason joined CNS as assistant general counsel in March 2023. As general counsel, she will oversee all aspects of the organization’s legal, risk management and regulatory performance efforts. Mason will provide oversight across all seven CNS clinics throughout California and Texas. Mason received her Juris Doctor degree from Southwestern Law School and has more than 10 years of experience as a trial attorney, primarily representing hospitals, medical groups, physicians and attorneys. The CNS Bakersfield clinic is the company’s flagship location, established in 1980. CNS has two other clinics across California in Los Angeles and San Francisco, as well as four Texas clinics in Dallas, Fort Worth, Houston and Austin. Through inpatient, outpatient, day treatment and residential rehabilitation programs, CNS’ facilities provide tailored neurorehabilitation therapy to patients. “Centre for Neuro Skills is not only an industry leader in post-acute neurorehabilitation services but also a pioneer in healthcare with unmatched passion, innovation and growth,” said Mason. “It is an honor and privilege to serve as general counsel for CNS, and contribute to making a positive impact on our patients’ lives.” *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 24, 2024 07:00 AM Pacific Standard Time

Image

CRAIG KNIPPENBERG, LCSW, M.DIV., RELEASES SECOND PARENTING GUIDEBOOK, SHAME-FREE PARENTING

Knippenberg, Patterson, Langley & Associates

Craig A. Knippenberg, LCSW, M.Div., a Denver-based mental health counselor with four decades of family therapy experience, and founder/host of the Legit Parenting podcast, announced today the release of his second book, Shame-Free Parenting ( Illumify Media Global ), a parenting guide for building family resiliency. In its first six weeks on Amazon, the book hit #1 in Kindle sales across all parenting books. In Shame-Free Parenting, Knippenberg demystifies many challenges associated with parenting today, which can result in over-protective child-rearing approaches. Now – more than ever – parents, children and families are faced with trying times as the world’s current events and social media platforms elicit a plethora of mixed feelings and emotions. Knippenberg believes that “ a pandemic of fragility has arisen amongst our children and teens, ” driven by modern-day culture and events. He also likens the smartphone to a modern pandora’s box that -- in combination with modern cultural issues, such as the impact and aftermath of COVID-19, school shootings, climate change, and persistent news coverage of war and social conflicts -- creates a state of chronic stress. He elaborates on these and other theories in the book. Loaded with judgment-free parenting wisdom and invaluable resources, Shame-Free Parenting inspires parents to build families capable of not only withstanding such challenges but also affording them ways to flourish amid them. In the book, parents will discover: How to let go of guilt/shame and the importance of being just this side of good enough A roadmap for understanding pivotal aspects of child-rearing, with tangible techniques for forging meaningful connections with children while championing their autonomy A holistic approach to emotions, boundaries and acceptance, all focused on progress A timely exploration of contemporary challenges – from the allure of TikTok and gaming to hard conversations about school shootings, the book features the essence and importance of structure, resourcefulness and steering young minds toward a driven purpose A call to action: embrace family spontaneity, adventure and community service as instrumental avenues for cementing ties and imparting core values “As a family therapist for more than 40 years, I’ve listened and witnessed. I have had the opportunity to gather substantial, firsthand accounts and information that has armed me with vast knowledge about navigating today’s ever-evolving landscape for children, teens and parents alike. I captured these experiences in my newest book and provided strategies and tips to help families connect and stay strong together,” Knippenberg said. “In Shame-Free Parenting, I help families better understand how children's brains work so they can foster both deeper connection and independence without guilt or shame. Building strong families is what healthy parenting is all about. It truly is the foundation of any successful family unit,” Knippenberg added. Michele Borba, ED.D., a best-selling author also endorsed by Harvard’s Robert Brooks, PhD, commented on Shame-Free Parenting: “Stellar! Given the modern cultural issues which face families, it’s imperative to focus on resiliency and problem solving.” Shame-Free Parenting is available at local bookstores or on Amazon. Legit Parenting is available through the Apple Store or on Spotify. Knippenberg’s first book Wired and Connected: Brain-Based Solutions To Ensure Your Child’s Social and Emotional Success, released in 2019, provides brain-based solutions for ensuring social skills and emotional success of children. About Craig A. Knippenberg Craig A. Knippenberg, LCSW, M.Div., is a Denver-based mental health therapist who has garnered significant expertise working with children and families throughout his four decades in private practice and while serving as a school consultant for 40+ years. While dedicating his career to educating and treating the behavioral, emotional and social needs of children and adolescents, Knippenberg founded Colorado’s largest, solely owned private mental health practice specializing in child and adolescent neurobehavioral disorders. He also earned notoriety for creating the CONNECT Social Skills Group Program 42 years ago, which spans socialization groups targeted at helping children navigate the ups and downs of childhood and adolescence, CONNECT has helped thousands of children grow and mature. Knippenberg hosts the Legit Parenting podcast, combining his four-plus decades of experience working with families and kids with his current brain-based research and pertinent tools, to help parents support the mental well-being of their children. Knippenberg holds a master's degree in Clinical Social Work from the University of Denver and a Master of Divinity with a focus on pastoral counseling from the Iliff School of Theology in Denver. For more information, please visit www.legitparenting.com or follow Knippenberg on LinkedIn, YouTube and Instagram. Contact Details PAIRELATIONS, LLC Susan Turkell +1 303-766-4343 sturkell@pairelations.com Company Website http://www.legitparenting.com/

January 24, 2024 08:00 AM Eastern Standard Time

Image

RZ Publish Nooro Foot Massager Reviews: Why It Is Used In The United States?

Spark Metro PR

Are you tired of living with constant burning and tingling in your feet due to neuropathy? Frustrated with painkillers that merely numb the discomfort without addressing the root cause? If so, you're not alone. Many have experienced the struggle of seeking relief from neuropathic pain, only to find temporary solutions. However, you are lucky to have come across this review because it is a comprehensive report about a breakthrough device popularly known as Nooro Foot Massager that goes beyond masking the symptoms, offering a chance to reverse nerve damage and regain a life free from persistent foot pain. In a world where traditional remedies may involve uncomfortable movements, Dr. Jeremy Campbell, in collaboration with the innovative med tech startup Nooro, introduces Nooro Foot Massager as a simple at-home solution for foot pain powered by Neuromuscular Electrical Stimulation (NMES) technology. This is where the story takes a turn towards hope and healing. Are you ready to break free from neuropathic pain and experience the relief you've been longing for? The Nooro Foot Massager might just be your key to a new lease on life. What Is Nooro Foot Massager? Nooro Foot Massager is a revolutionary at-home solution developed through the collaboration of Dr. Jeremy Campbell and the innovative med tech startup, Nooro. Designed to address neuropathic foot pain, Nooro Foot Massager device employs NeuroMuscular Electrical Stimulation (NMES) technology to offer relief in the comfort of your home. Specifically named the Nooro Foot Massager, this device stands out by delivering a unique combination of targeted electric impulses deep into the tissues of your feet and legs. The primary goal? To kickstart blood circulation, a crucial factor in providing the oxygen necessary for nerve recovery. By enhancing blood flow to your feet, the Nooro Foot Massager becomes a catalyst for nerve repair and healing. This breakthrough approach holds the promise of reducing the burning pain, tingling, and numbness associated with neuropathy. The ultimate result? A chance to reclaim the activities you love, free from the constant foot pain and swelling that may have confined you. This user-friendly device opens doors to a life where neuropathic pain no longer dictates your daily experiences, offering a pathway to comfort and mobility. In essence, the Nooro Foot Massager is more than just a device – it's a transformative tool designed to empower you on your journey to relief from neuropathic foot pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Features (Nooro Foot Massager Reviews USA) EMS Technology: The Nooro Foot Massager employs advanced NeuroMuscular Electrical Stimulation (EMS) technology. This technology facilitates the penetration of steady electric impulses deep into the tissues of the feet and legs, aiming to relieve muscle tension, increase blood circulation, and strengthen weakened muscles. Cordless Convenience: The Nooro EMS Foot Massager offers a cordless design, eliminating the hassle of dealing with tangled cords during use. Charging is simple using the provided electricity plug and cable, ensuring a convenient and clutter-free experience. Optional Preparatory Step: While optional, the recommendation to wash your feet and remove excess skin before using the massager adds a thoughtful touch. This preparatory step enhances the overall effectiveness of the massage treatment, promoting a more thorough and satisfying experience. Versatile Massage Modes: The device features a variety of different modes, providing users with options to cater to their specific needs. Whether you're looking to relax after a long day or target particular muscle groups causing discomfort, the Nooro Foot Massager's versatility ensures a customized and enjoyable experience. Adjustable Intensity Levels: Tailoring the massage experience to individual preferences, the massager offers a mind-bending number of speed settings. This wide range allows users to find the perfect intensity level, ensuring that the massage is both effective and comfortable for various muscle groups. User-Friendly Operation: The massager's simplicity is a standout feature. With easy-to-follow steps—place your feet on the foot pad, select the mode, and adjust intensity—you can initiate the massage effortlessly. The user-friendly design ensures that anyone can enjoy the benefits without a steep learning curve. Effective Neuropathy Relief: The Nooro Foot Massager is specifically designed to address neuropathic foot pain. By enhancing blood circulation, relieving muscle tension, and providing a targeted massage experience, the device aims to alleviate burning pain, tingling, and numbness. Users can experience liberation from the challenges of neuropathy, promoting overall foot health and well-being. Benefits Of Nooro Foot Massager Pain Alleviation: A primary benefit of the Nooro Foot Massager is its ability to ease neuropathic foot pain. By employing advanced EMS technology, the massager delivers targeted electric impulses to alleviate burning sensations and discomfort associated with neuropathy. Users may experience significant relief from persistent foot pain. Tingling Relief: This innovative EMS massager targets nerve-related tingling sensations by enhancing blood circulation. Through its unique combination of electric impulses, the Nooro Foot Massager aims to improve oxygen supply to peripheral nerves, reducing tingling and promoting a sense of comfort. Numbness Reduction: For individuals experiencing numbness due to neuropathy, the Nooro Foot Massager offers hope. By increasing blood flow to the feet and facilitating nerve repair, the device strives to reduce numbness, allowing users to regain sensation in their extremities. Improved Blood Circulation: A core benefit lies in the massager's ability to enhance blood circulation. The EMS technology stimulates blood flow to the feet and legs, ensuring a continuous supply of oxygen to nerve cells. Improved circulation contributes not only to pain relief but also to overall foot health. Muscle Strengthening: Beyond addressing neuropathic pain, the Nooro Foot Massager helps strengthen weakened muscles. The electric impulses penetrate deep into the tissues, promoting muscle stimulation. This additional benefit contributes to overall foot strength and may aid in preventing future discomfort. Convenience and Comfort: The cordless design, along with the straightforward operational steps, adds a layer of convenience to the user experience. The Nooro Foot Massager provides a hassle-free solution for those seeking comfort and relief. Users can enjoy the benefits of a personalized massage without the inconvenience of cords or complicated setup. How Does Nooro Foot Massager Work? (Nooro Foot Massager Reviews) The Nooro EMS Foot Massager operates on advanced EMS (Electrical Muscle Stimulation) technology, offering a multi-faceted approach to relieving discomfort. True to its name, using this device is as simple as placing your feet on it and letting it work its magic. Specifically, Nooro EMS Foot Massager works by increasing blood flow to your feet, the massager facilitates the delivery of much-needed oxygen to nerve cells. This groundbreaking approach opens the door to nerve repair and healing, reducing burning pain, tingling, and numbness. But here's the beauty of it – as long as your nerves are alive, there's hope for reversal. The National Institute of Health emphasizes the regenerative capacity of peripheral nerves when the underlying nerve cell remains intact. The Nooro Foot Massager becomes a tool for revitalization, offering relief and a chance to reclaim a life without constant foot pain. This innovative massager employs steady electric impulses that penetrate deep into your feet and legs, effectively targeting muscle tension. The result? Relaxation of tense muscles, which is essential for alleviating discomfort associated with neuropathic foot pain. What sets the Nooro Foot Massager apart is its versatility. With a variety of modes and an impressive array of speed settings, the device allows you to tailor your experience to address specific muscle groups. This flexibility ensures that you can find a satisfying combination, catering to the unique needs of whatever muscle group is causing you distress. In essence, the Nooro Foot Massager is designed to be user-friendly and customizable. Its cutting-edge EMS technology aims to enhance blood circulation, relieve muscle tension, and strengthen weakened muscles, all while providing a hassle-free experience. So, whether you're looking to unwind after a long day or target specific muscle groups causing discomfort, this device offers a personalized solution to meet your needs. Who Needs Nooro Foot Massager? Foot Pain and Discomfort: If your feet hurt or feel uncomfortable, the Nooro Foot Massager can give you relief and make you feel better. Plantar Fasciitis: If you have plantar fasciitis (pain in the bottom of your feet), using the massager can help ease the pain and make your feet more comfortable. Athletes and Runners: Athletes and runners can use the massager to relax their muscles and recover faster after exercising. Diabetes: If you have diabetes and your feet need extra care, the Nooro Foot Massager can be part of your routine to keep your feet comfortable. Swelling: If your feet are swollen, especially during pregnancy or due to certain health issues, the Nooro Foot Massager can help reduce the swelling. General Well-being: If you just want to feel better overall and more relaxed, using the Nooro Foot Massager can contribute to your well-being. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE AT A MASSIVE DISCOUNT Does Nooro EMS Foot Massager Really Work? Absolutely, the Nooro EMS Foot Massager has garnered positive reviews from satisfied customers, attesting to its effectiveness. Users express genuine satisfaction with the relief it provides, particularly in addressing knee-related concerns. Many have reported that it contributes to a positive sensation in their knees, offering comfort and support, especially before bedtime. Customers dealing with foot pains have found solace in the Nooro Foot Massager. The device seems to provide tangible relief, soothing discomfort associated with foot pains. The positive feedback highlights the impact of the massager in helping alleviate foot-related issues, making it a promising solution for those seeking relief from foot pain. One user shared their experience, noting the immediate positive effects after just one use. This firsthand account emphasizes the rapid and noticeable benefits users can expect, further reinforcing the idea that the Nooro EMS Foot Massager indeed works to bring comfort and relief. In essence, the testimonials from customers reflect a consensus that the Nooro EMS Foot Massager is not just a device but a reliable solution that genuinely addresses pain and discomfort, particularly in the knees. The positive feedback from users reinforces the notion that the Nooro Foot Massager is effective in delivering the relief it promises. How To Use Nooro Foot Massager? Using the Nooro EMS Foot Massager is delightfully straightforward, making it a hassle-free addition to your routine. First and foremost, you'll appreciate the absence of annoying cords – charging is a breeze with the included electricity plug and cable that come with your order. Once charged, the process is as simple as 1-2-3. For an optimal experience, the second step is optional but recommended – give your feet a quick wash and remove any excess skin. This preparatory step significantly enhances the effectiveness of the massage treatment. Now, you're ready to indulge in the soothing benefits of the Nooro Foot Massager. Just place your feet on the foot pad, select your preferred mode, and adjust the intensity level of the massage to your liking. It's a customizable experience tailored to meet your unique needs. From there, all that's left to do is sit back comfortably and let the massager work its magic. As it eases pain, relieves tingling, and liberates you from the challenges of neuropathy, you'll find a newfound sense of comfort and relief. The Nooro Foot Massager brings simplicity and effectiveness together, making it a user-friendly solution for those seeking relief from neuropathic foot pain. Price Of Nooro Foot Massager And Where To Buy Nooro Foot Massager can be gotten directly from the manufacturer’s official website at the following prices: Single Unit: Buy one Nooro Foot Massager for $99.95. Two Units: Buy two Nooro Foot Massagers for $94.95 each. Total cost: $189.90. Three Units: Buy three Nooro Foot Massagers for $89.95 each. Total cost: $269.85. Four Units: Buy four Nooro Foot Massagers for $87.95 each. Total cost: $351.80. Six Units: Buy six Nooro Foot Massagers for $84.95 each. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Nooro Foot Massager Reviews Consumer Reports And Customer Complaints The Nooro EMS Foot Massager has received overwhelmingly positive consumer reports, with an impressive 4.8-star rating and a noteworthy achievement of zero customer complaints. Thousands of individuals have experienced successful outcomes in reversing neuropathy with this device, highlighting its efficacy and customer satisfaction. Harry Keegan - “Superb relaxation, it's not bulky, so you can take it anywhere, cheaper than other massagers, does what it says. You'll love the "cupping mode". Many intensity options (up to 19). It's a great product with fast shipping! My wife loves it…” Debra Peyton - “Should have bought Nooro Foot Massager earlier, exactly what I needed for my neuropathy-pained-feet. Honestly, I can walk and move with just minimal pain. I've only used it for like 2 days and I have felt better than I have in the past 2 years!!!” Clara Milton - “I absolutely love my Nooro EMS Foot Massager massager, had to get one for my daughter today since she wont stop using mine!” Final Verdict On Nooro EMS Foot Massager Reviews The overwhelming positive reviews and testimonials for the Nooro Foot Massager paint a compelling picture of its effectiveness and customer satisfaction. With a remarkable 4.8-star rating and zero customer complaints, it stands out as a reliable solution for those seeking relief from neuropathic foot pain. Customers like Harry Keegan commend the massager for its superb relaxation, portability, affordability, and diverse intensity options. The mention of the "cupping mode" adds to the device's appeal. Debra Peyton's experience reinforces the quick and tangible relief the Nooro Foot Massager provides, enabling her to walk with minimal pain after just two days of use. Clara Milton's enthusiasm and the decision to purchase an additional massager for her daughter further underscore the positive impact and effectiveness of the device. In the final verdict, the Nooro Foot Massager emerges as a standout product, praised for its user-friendly design, versatility, and ability to address neuropathy-induced foot pain. The absence of customer complaints reinforces its credibility, making it a promising choice for those in search of a reliable and effective solution to neuropathic pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely substitutes for sound medical or financial advice from a licensed healthcare provider or certified financial advisor. Make sure to consult with a professional physician or financial consultant before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary. These products are not intended to diagnose, treat, cure or prevent any disease and do not provide any kind of get-rich money scheme. Reviewer is not responsible for pricing inaccuracies. Check product sales page for final prices. Contact Details Review Zenith Alex +1 302-597-6768 Alexreview@gmail.com Company Website https://reviewzenith.com

January 22, 2024 09:33 AM Eastern Standard Time

Image

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem

Ness Ziona, Israel, January 22, 2024, Kadimastem (TASE: KDST) and iTolerance Inc. announced today that the companies held a preliminary meeting with the INTERACT committee of the U.S Food and Drug Administration (FDA) on January 19 th, 2024 regarding the preclinical and clinical development leading toward commercialization of iTOL-102, a potential cure for diabetes that does not require chronic immune system suppression. Before the meeting, the companies received a response document from the FDA noting important feedback about the current preclinical plans which the companies intend to use for the advancement of their potential joint collaboration development plans. With the feedback from the INTERACT meeting received, the companies are working on the design and commencement of a clinical study of iTOL-102 that is planned to be submitted to the FDA for an IND in the future. Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “We are pleased with the continued progress of our research collaboration with Kadimastem. With the INTERACT meeting now complete and the feedback received from our discussions with FDA, we are evaluating next steps toward a potentially innovative cure for patients with Type 1 diabetes.” Kadimastem CEO Asaf Shiloni said, " Thanks to our scientific teams who presented the joint collaboration project in an impressive manner. I am convinced that the helpful meeting and the relevant feedback will contribute to the continued progress of our planned joint product development and hopefully provide a cure for those living with diabetes.” In May 2023, the companies announced their research collaboration agreement to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression and received a grant in the aggregate amount of US$1.0 million from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation. As part of the agreement, the companies are considering expanding their cooperation and advancing the development of iTOL-102. The joint project is based on Kadimastem’s diabetes product called IsletRx, which is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs). Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce and secrete dependently, the required amounts of insulin and glucagon, just like a healthy pancreas. iTolerance, headquartered in Miami, Florida, has developed an innovative platform technology (iTOL-100) intended to enable the transplantation of allogeneic cells without tissue matching and without the need for chronic treatments that suppress the immune system of the transplant recipient (immunosuppression). This platform technology was successfully demonstrated in preclinical experiments in large animals (non-human primates), where diabetes was cured by allogeneic transplantation, without the need for long-term immunosuppressive treatments. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is an early-stage privately-held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Kadimastem Asaf Shiloni CEO s.bazak@kadimastem.com iTolerance Jenene Thomas Chief Executive Officer, JTC Team, LLC +1 833-475-8247 iTolerance@jtcir.com Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

January 22, 2024 07:33 AM Eastern Standard Time

Image

News Release

Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)

CGR Spine

Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory from 2023 to 2032, with a significantly positive CAGR, according to Delveinsights. With the spinal cord injury market showing promising growth, let's explore key stocks that could offer potential returns in the evolving healthcare landscape. NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) is positioned as a pioneering force in biopharmaceuticals, with a primary focus on advancing the field of biologically-guided exosome therapy for traumatic spinal cord injuries. Founded on innovative technology, NurExone's flagship product, ExoPTEN, stands out as a potential game-changer. Administered intranasally, ExoPTEN represents a minimally invasive ExoTherapy designed to induce neuron regeneration and rewiring in traumatically damaged spinal cords. The company holds exclusive worldwide licenses from the Technion and Tel Aviv University, signifying its leadership in translating groundbreaking concepts into actionable solutions. Key milestones in NurExone's journey include a notable Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial interaction, held on August 29, 2023, provided clear guidance for the manufacturing, preclinical, and clinical development plans of ExoPTEN. The FDA's endorsement of NurExone's proposed ExoPTEN release testing strategy and toxicity study strategy sets the stage for submitting an Investigational New Drug (IND) application by Q4 2024, with Phase 1/2 human clinical studies anticipated to commence in 2025. In tandem with its commitment to acute spinal cord injury treatments, NurExone secured a $1 million New Israeli Shekels grant from the Israel Innovation Authority. This grant fosters collaboration with Inteligex Inc. to develop an innovative hybrid therapy targeting chronic spinal cord injuries. The collaboration, approved by the Israel-Canada bilateral Eureka program, broadens NurExone's potential market focus. The FDA's grant of Orphan-Drug Designation (ODD) for ExoPTEN therapy on October 30, 2023, marks a pivotal milestone. This designation recognizes the therapy's potential impact on acute spinal cord injuries, offering NurExone significant benefits such as market exclusivity, financial incentives, and regulatory support. The ODD status streamlines the company's go-to-market strategy, signaling a promising path for ExoPTEN. NurExone's commitment to continuous innovation is evident in its laboratory tests unveiled on November 29, 2023. These tests showcased two proprietary small inhibiting RNA sequences targeting the Peri-Neural Network (PNN) complex, representing a significant advancement in spinal cord injury treatment. The potential for two new products in the company's portfolio underscores NurExone's dedication to diversifying its molecular arsenal. The company's financial vitality received a boost with the closure of a non-brokered private placement on January 5, 2024. Raising CAD$1,985,758.04, this investment reflects strong investor confidence in NurExone's technology and direction. The proceeds are earmarked for advancing development activities, expanding the intellectual property portfolio, and supporting overall corporate objectives. More recently, on January 17, 2024, NurExone's collaborative agreement with Inteligex Inc. was officially underway. This collaboration aims to combine Inteligex's expertise in cell-based therapies with NurExone's innovative exosome platform, focusing on developing therapies for chronic spinal cord injuries. Additionally, NurExone has entered into an agreement with bullVestor Medien GmbH to enhance awareness of its products in German-speaking countries. NurExone Biologic Inc. is at the forefront of biologically-guided exosome therapy, supported by a number of milestones and technological advancements. The journey from FDA interactions to collaborative partnerships and financial investments paints a comprehensive picture of NurExone's trajectory, positioning the company as a leader in reshaping the landscape of regenerative therapies for spinal cord injuries. Nevro Corporation (NYSE: NVRO), headquartered in Redwood City, California, stands at the forefront of the medical device industry, specializing in transformative solutions for chronic pain treatment. Focused on their mission to alleviate debilitating pain, Nevro developed the groundbreaking 10 kHz Therapy—an evidence-based, non-pharmacologic innovation that has positively impacted over 100,000 patients worldwide. One notable achievement is the publication of 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) trial in the Journal of Neurosurgery: Spine. This trial demonstrated the profound benefits of Nevro's high-frequency spinal cord stimulation (SCS) system in managing chronic back pain. Patients experienced significant pain relief, improved function, and enhanced quality of life, with a noteworthy reduction in opioid usage. Moreover, Nevro's strategic acquisition of Vyrsa Technologies expands its portfolio to address chronic sacroiliac joint pain—an essential move in a market valued at over $2 billion and expected to witness double-digit growth. This acquisition positions Nevro to offer tailored therapies, driving long-term shareholder value and contributing to growth projections in 2024. The company's financial performance, highlighted in the fourth-quarter 2023 results, exceeded expectations, showcasing consistent growth and a focus on key pillars: commercial execution, market penetration, and profit progress. Despite a restructuring initiative, Nevro remains committed to innovation, as evidenced by its partnership with Carelon Healthcare to broaden spinal cord stimulation coverage for painful diabetic neuropathy. As Nevro continues to pioneer advancements in chronic pain treatment, its comprehensive solutions and strategic initiatives position it as a key player in the evolving landscape of medical device innovation. Stryker Corporation (NYSE: SYK), a trailblazer in the medical technology domain, recently achieved a historic milestone, surpassing $20 billion in annual sales for the first time in December 2023. This achievement underscores Stryker's global impact on over 130 million patients annually and solidifies its position as a major leader in the medical device industry. Specializing in MedSurg, Neurotechnology, Orthopaedics, and Spine, Stryker stands out for its commitment to innovation and improving healthcare outcomes. In the realm of spine-related technology, the company's Spine division has demonstrated notable advancements, showcasing a dedication to state-of-the-art solutions for surgeons and patients alike. Robbie Robinson, President of the Spine division, emphasized the company's exciting year with multiple product launches, highlighting the continued growth of the Spine business. Among these launches, the Q Guidance System with Spine Guidance Software stands out, receiving the prestigious 2022 Best Technology in Spine award for its contributions to surgical spine planning and navigation. Stryker's commitment to excellence is further evident in products like the Monterey AL Interbody System, incorporating Tritanium In-Growth Technology, and the Bone Mill+, designed for enhanced efficiency in bone milling. The OmniCurve curved balloon system adds another dimension to Stryker's offerings, providing surgeons with advanced capabilities and control. As Stryker achieves record-breaking financial success, its continuous innovation in spine-related technology positions the company as a key player with substantial potential in the medical device sector. Stay tuned for more insights into Stryker's financial results during its upcoming Q4 and full-year earnings call on January 30, 2024. Boston Scientific (NYSE: BSX), a global medical technology leader, has been at the forefront of transforming lives through innovative medical solutions for over 40 years. With a commitment to advancing science and addressing unmet patient needs, the company provides high-performance solutions that enhance healthcare outcomes. In a significant move, Boston Scientific recently completed the acquisition of Relievant Medsystems Inc., marking a milestone in its chronic pain portfolio. Relievant is renowned for its Intracept Intraosseous Nerve Ablation System, the only FDA-cleared therapy for vertebrogenic pain, a form of chronic low back pain. This acquisition strengthens Boston Scientific's position in advanced interventional chronic pain treatments, offering physicians a comprehensive selection of evidence-based options. The Intracept system utilizes basivertebral nerve ablation therapy and has garnered national coverage from major insurers like Anthem Blue Cross Blue Shield and Humana. These coverage expansions, along with existing agreements with Cigna Healthcare and local Medicare plans, significantly increase access to intracept treatments for over 150 million lives. Jim Cassidy, President of Neuromodulation at Boston Scientific, expressed enthusiasm about the revolutionary therapy's potential to help more people suffering from chronic pain. The acquisition, involving an $850 million upfront cash payment and additional contingent payments based on sales performance, is poised to enhance Boston Scientific's capabilities in addressing multiple pain targets. This strategic move reflects Boston Scientific's commitment to offering physicians and patients a diverse range of evidence-based treatment options, further solidifying its position as a leader in the evolving landscape of chronic pain solutions. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR), owned by RazorPitch Inc., is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by Awareness Consulting to produce and distribute this content related to NRX. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-748-6862 markrmckelvie@gmail.com

January 22, 2024 05:00 AM Eastern Standard Time